デフォルト表紙
市場調査レポート
商品コード
1401820

アンチセンス・RNAI治療薬市場:技術別、用途別、投与経路別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測

Antisense & RNAI Therapeutics Market, By Technology, By Application, By Route of Administration, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030


出版日
ページ情報
英文 316 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
アンチセンス・RNAI治療薬市場:技術別、用途別、投与経路別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2024年01月01日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

アンチセンス・RNAI治療薬の市場規模は2022年に38億米ドルと評価され、2023年から2030年にかけてCAGR 19.1%で拡大する見込みです。

アンチセンス・RNAI治療薬市場-市場力学

希少疾患の治療におけるアンチセンス・RNAI治療薬の変革的インパクトが市場需要を促進

市場を牽引する主な要因は、希少疾患の治療におけるアンチセンス・RNAI治療薬の画期的なインパクトです。遺伝子サイレンシングを用いることで、これらの治療薬は疾患関連タンパク質の産生を阻止し、特に脊髄性筋萎縮症やヘテロ接合性家族性高コレステロール血症などの疾患に恩恵をもたらします。疾患の原因となるmRNAを標的とするRNAi治療の精度と選択性は、希少疾患に対する先進的な治療法として支持されています。このようなRNAi治療薬に対する需要の急増は、研究開発投資の増加や有望なパイプライン製品によって補完され、市場拡大を後押しする主要な要因となっています。

アンチセンスとRNAI治療薬市場-主要インサイト

弊社のリサーチアナリストの分析によると、世界市場は予測期間(2023-2030年)に約19.1%のCAGRで毎年成長すると予測されています。

技術セグメンテーションに基づくと、アンチセンスRNAは2022年に最大市場シェアを示すと予測されました。

投与経路別では、遺伝性疾患が2022年の主要タイプでした。

地域別では、北米が2022年の売上高をリードしました。

アンチセンス・RNAI治療薬市場-セグメンテーション分析:

アンチセンス・RNAI治療薬の世界市場は、技術、用途、投与経路、地域に基づいて区分されます。

市場は技術に基づいて2つのカテゴリーに分けられます:RNA干渉とアンチセンスRNAです。2022年には、アンチセンスRNA部門が収益の最大シェアを占めました。この部門は主に収益をリードしており、様々な病態を管理するための試験が活発に行われています。タンパク質と遺伝子の両方の発現を制御するために利用されるこの技術は、心臓血管、呼吸器、神経変性、遺伝性疾患など幅広い応用を示し、この分野の著しい成長を予見させる。例えば、2021年12月にUMass Chan Medical Schoolで行われた臨床試験では、アンチセンスオリゴヌクレオチドを用いた変異型筋萎縮性側索硬化症(ALS)遺伝子の安全な抑制が実証されました。

市場は投与経路に基づいて9つのカテゴリーに分けられる:遺伝子疾患、がん、感染症、神経変性疾患、心臓代謝・腎臓疾患、眼疾患、呼吸器疾患、皮膚疾患、その他です。2022年に最も高い売上シェアを占めたのは遺伝子疾患分野でした。デュシェンヌ型筋ジストロフィー(DMD)や脊髄性筋萎縮症のような疾患を管理する必要性の高まりが、オリゴヌクレオチド製品の使用を促進すると予想されています。オリゴヌクレオチド医薬品の領域における調査活動は急速に拡大しており、調査件数の増加からも明らかです。企業は、遺伝性疾患を治療するために設計された製品の薬事承認を追求しています。例えば、2019年12月、DMDに罹患している人のためのアンチセンスオリゴヌクレオチド治療薬であるゴロジルセンは、食品医薬品局(FDA)から承認を受けた。

アンチセンス・RNAI治療薬市場-地理的洞察

この市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広く分布しています。これらの地域は、ビジネスを展開する国によってさらに分けられます。

アンチセンス・RNAI治療薬市場-競合情勢:

アンチセンス&RNAi治療薬市場では、企業はさまざまな主要戦略を展開し、その地位を強化しています。各社は広範な研究開発を優先し、最先端技術に投資して正確な遺伝子ターゲットを突き止め、効果的な治療分子を創出しています。パイプラインの多様化は最優先課題であり、幅広い疾患を網羅し、市場参入の幅を広げることを目指しています。研究機関や産業界との協力的パートナーシップは、進捗を早め、リソースの共有を促進します。同時に、企業は規制基準の厳格な遵守を徹底し、承認プロセスを効率的に進める。承認後の戦略的商業化計画には、ターゲットを絞ったマーケティングとアクセシビリティ・イニシアチブを含めることが、採用の成功には不可欠です。さらに、デリバリーシステムの継続的な進歩は、治療効果を最適化するための極めて重要な焦点です。このような包括的な戦略により、アンチセンス・RNAi療法はヘルスケアの現場で進歩し、受け入れられています。企業は、アンチセンスとRNAi技術に特化した進歩を通じて資本を投下しています。

目次

第1章 アンチセンス・RNAI治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 アンチセンス・RNAI治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 アンチセンス・RNAI治療薬業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 アンチセンス・RNAI治療薬市場:COVID-19の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 アンチセンス・RNAI治療薬市場情勢

  • アンチセンス・RNAI治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 アンチセンス・RNAI治療薬市場- 技術別

  • 概要
    • 技術別セグメントシェア分析
    • RNA干渉
    • アンチセンスRNA

第8章 アンチセンス・RNAI治療薬市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • 遺伝病
    • がん
    • 感染症
    • 神経変性疾患
    • 心臓代謝障害および腎臓障害
    • 眼疾患
    • 呼吸器疾患
    • 皮膚疾患
    • その他

第9章 アンチセンス・RNAI治療薬市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 静脈注射
    • くも膜下腔内注射
    • 皮下注射
    • その他

第10章 アンチセンス・RNAI治療薬市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋(APAC)
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- アンチセンス・RNAI治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • GSK plc
    • Olix Pharmaceuticals, Inc.
    • Sanofi
    • Alnylam Pharmaceuticals, Inc.
    • Arbutus Biopharma
    • Benitec Biopharma Inc.
    • Silence Therapeutics
    • Ionis Pharmaceuticals, Inc
    • Bio-Path Holdings Inc.
    • Antisense Therapeutics Limited.
    • その他

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antisense & RNAI Therapeutics Market: Technology Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Technology
  • TABLE Global Antisense & RNAI Therapeutics Market, by Technology 2018-2030 (USD Million)
  • TABLE Antisense & RNAI Therapeutics Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Antisense & RNAI Therapeutics Market, by Application 2018-2030 (USD Million)
  • TABLE Antisense & RNAI Therapeutics Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Antisense & RNAI Therapeutics Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Antisense & RNAI Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antisense & RNAI Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antisense & RNAI Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antisense & RNAI Therapeutics Market, by Technology, 2018-2030 (USD Million)
  • TABLE North America Antisense & RNAI Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE North America Antisense & RNAI Therapeutics Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Antisense & RNAI Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antisense & RNAI Therapeutics Market, by Technology, 2018-2030 (USD Million)
  • TABLE Europe Antisense & RNAI Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Antisense & RNAI Therapeutics Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antisense & RNAI Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antisense & RNAI Therapeutics Market, by Technology, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antisense & RNAI Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antisense & RNAI Therapeutics Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Antisense & RNAI Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antisense & RNAI Therapeutics Market, by Technology, 2018-2030 (USD Million)
  • TABLE Latin America Antisense & RNAI Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Antisense & RNAI Therapeutics Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antisense & RNAI Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antisense & RNAI Therapeutics Market, by Technology, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antisense & RNAI Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antisense & RNAI Therapeutics Market, by Route of Administration, 2018-2030 (USD Million)
目次
Product Code: ANV2006

REPORT HIGHLIGHT

Antisense & RNAI Therapeutics Market size was valued at USD 3,800 Million in 2022, expanding at a CAGR of 19.1% from 2023 to 2030.

Antisense technology, acknowledged for gene expression manipulation, stands as a successful treatment avenue for numerous medical conditions. The use of Antisense and RNAi therapies for rare diseases has notably improved therapeutic outcomes. For example, Antisense Oligonucleotides (ASOs) have gained approval for treating rare neurological conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), signaling anticipated growth in the upcoming years. Additionally, augmented R&D funding and a robust product pipeline are expected to drive market expansion. For instance, in January 2023, Agilent invested USD 725 million in expanding manufacturing capabilities for nucleic acid-based therapeutics, including antisense therapies. The scarcity of global treatment options for rare diseases has spurred increased funding and research endeavors focused on developing novel treatments for these conditions.

Antisense & RNAI Therapeutics Market- Market Dynamics

Transformative impact of antisense and RNAi therapeutics in treating rare diseases to propel market demand

The primary factors driving the market are the transformative impact of antisense and RNAi therapeutics in treating rare diseases. By employing gene silencing, these therapies prevent the production of disease-related proteins, notably benefiting conditions like spinal muscular atrophy and heterozygous familial hypercholesterolemia. The precision and selectivity of RNAi treatments, which target disease-causing mRNA, position them as advanced and favored treatments for rare ailments. This surge in demand for RNAi therapeutics acts as a key driver, complemented by increased R&D investment and promising pipeline products, collectively propelling market expansion.

Antisense & RNAI Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.1% over the forecast period (2023-2030)

Based on Technology segmentation, antisense RNA was predicted to show maximum market share in the year 2022

Based on Route of Administration segmentation, genetic disease was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Antisense & RNAI Therapeutics Market- Segmentation Analysis:

The Global Antisense & RNAI Therapeutics Market is segmented on the basis of Technology, Application, Route of Administration, and Region.

The market is divided into two categories based on Technology: RNA Interference and Antisense RNA. In 2022, the antisense RNA division represented the largest share of revenue. This segment has predominantly led in revenue generation and is actively undergoing trials for managing various conditions. Utilized for regulating both protein and gene expression, this technology exhibits broad applications across cardiovascular, respiratory, neurodegenerative, and genetic disorders, foreseeing significant segmental growth. For instance, a clinical trial at UMass Chan Medical School in December 2021 demonstrated the safe suppression of the mutant amyotrophic lateral sclerosis (ALS) gene using antisense oligonucleotides.

The market is divided into nine categories based on Route of Administration: Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardio Metabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders and Others. The genetic disorder sector commanded the highest revenue share in 2022. The growing necessity to manage diseases like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy is expected to drive the usage of oligonucleotide products. Research endeavors in the realm of oligonucleotide medications are rapidly expanding, evident from the increasing number of research studies. Companies are pursuing regulatory approvals for products designed to treat genetic diseases. For instance, in December 2019, golodirsen, an antisense oligonucleotide therapy for individuals afflicted with DMD, received approval from the Food and Drug Administration (FDA).

Antisense & RNAI Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Antisense & RNAI Therapeutics Market- Competitive Landscape:

In the Antisense & RNAi Therapeutics Market, companies deploy various key strategies to bolster their position. They prioritize extensive research and development, investing in cutting-edge technologies to pinpoint precise gene targets and create effective therapeutic molecules. Diversifying pipelines remains a top priority, aiming to encompass a wide array of diseases and broaden market reach. Collaborative partnerships with research institutions and industry counterparts expedite progress and facilitate resource sharing. Concurrently, companies ensure rigorous compliance with regulatory standards, efficiently navigating approval processes. Post-approval, strategic commercialization plans, inclusive of targeted marketing and accessibility initiatives, are vital for successful adoption. Furthermore, continuous advancements in delivery systems are a pivotal focus to optimize therapeutic efficacy. These comprehensive strategies collectively drive the progression and acceptance of antisense and RNAi therapies within the healthcare landscape. Companies capitalize on antisense & RNAi technologies through dedicated advancements.

Recent Developments:

In April 2020, Alnylam Pharmaceuticals, Inc. partnered with Blackstone, with Blackstone investing USD 2 billion to accelerate RNAi therapeutics advancement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET KEY PLAYERS

  • GSK plc
  • Olix Pharmaceuticals, Inc.
  • Sanofi
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma
  • Benitec Biopharma Inc.
  • Silence Therapeutics
  • Ionis Pharmaceuticals, Inc
  • Bio-Path Holdings Inc.
  • Antisense Therapeutics Limited.
  • Others

GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY TECHNOLOGY

  • RNA Interference
  • Antisense RNA

GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY APPLICATION

  • Neurodegenerative Disorders
  • Cardio Metabolic & Renal Disorders
  • Genetic Disease
  • Cancer
  • Infectious Disease
  • Ocular Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Others

GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • Intravenous Injections
  • Intrathecal Injections
  • Subcutaneous Injections
  • Other Delivery Methods

GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antisense & RNAI Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antisense & RNAI Therapeutics Market Snippet by Technology
    • 2.1.2. Antisense & RNAI Therapeutics Market Snippet by Application
    • 2.1.3. Antisense & RNAI Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Antisense & RNAI Therapeutics Market Snippet by Country
    • 2.1.5. Antisense & RNAI Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Antisense & RNAI Therapeutics Key Market Trends

  • 3.1. Antisense & RNAI Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antisense & RNAI Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antisense & RNAI Therapeutics Market Opportunities
  • 3.4. Antisense & RNAI Therapeutics Market Future Trends

4. Antisense & RNAI Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antisense & RNAI Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antisense & RNAI Therapeutics Market Landscape

  • 6.1. Antisense & RNAI Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antisense & RNAI Therapeutics Market - By Technology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Technology, 2022 & 2030 (%)
    • 7.1.2. RNA Interference
    • 7.1.3. Antisense RNA

8. Antisense & RNAI Therapeutics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Genetic Disease
    • 8.1.3. Cancer
    • 8.1.4. Infectious Disease
    • 8.1.5. Neurodegenerative Disorders
    • 8.1.6. Cardio Metabolic & Renal Disorders
    • 8.1.7. Ocular Disorders
    • 8.1.8. Respiratory Disorders
    • 8.1.9. Skin Disorders
    • 8.1.10. Others

9. Antisense & RNAI Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 9.1.2. Intravenous Injections
    • 9.1.3. Intrathecal Injections
    • 9.1.4. Subcutaneous Injections
    • 9.1.5. Other Delivery Methods

10. Antisense & RNAI Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Antisense & RNAI Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Antisense & RNAI Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Antisense & RNAI Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Antisense & RNAI Therapeutics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Antisense & RNAI Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Antisense & RNAI Therapeutics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
    • 11.2.2. Olix Pharmaceuticals, Inc.
    • 11.2.3. Sanofi
    • 11.2.4. Alnylam Pharmaceuticals, Inc.
    • 11.2.5. Arbutus Biopharma
    • 11.2.6. Benitec Biopharma Inc.
    • 11.2.7. Silence Therapeutics
    • 11.2.8. Ionis Pharmaceuticals, Inc
    • 11.2.9. Bio-Path Holdings Inc.
    • 11.2.10. Antisense Therapeutics Limited.
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us